Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines

Journal of Immunology

Volumn 176, Issue 3, 2006, Pages 1447-1455

  Dolan, Brian P ^a   Gibbs Jr , Kenneth D ^a   Ostrand Rosentoerg, Suzanne ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CD4 LYMPHOCYTE COUNT; CELL FUNCTION; COMPLEX FORMATION; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; DRUG DESIGN; GENOTYPE; IMMUNOGENETICS; IMMUNOGENICITY; IMMUNOSTIMULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

EID: 31144469922     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.3.1447     Document Type: Article

References (52)

1. Klebanoff, C. A., H. T. Khong, P. A. Antony, D. C. Palmer, and N. P. Restifo. 2005. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 26: 111-117.
2. Finn, O. J. 2003. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3: 630-641.
3. Banchereau, J., and A. K. Palucka. 2005. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5: 296-306.
4. Chen, L., S. Ashe, W. A. Brady, I. Hellstrom, K. E. Hellstrom, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71: 1093-1102.
5. Daniel, P. T., A. Kroidl, S. Cayeux, R. Bargou, T. Blankenstein, and B. Dorken. 1997. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J. Immunol. 159: 3808-3815.
6. + T cells by B7-transfected melanoma cells. Science 259: 368-370.
7. Yang, G., K. E. Hellstrom, I. Hellstrom, and L. Chen. 1995. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 Costimulatory molecules. J. Immunol. 154: 2794-2800.
8. Cayeux, S., G. Richter, G. Noffz, B. Dorken, and T. Blankenstein. 1997. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. J. Immunol. 158: 2834-2841.
9. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181: 619-629.
10. Ostrand-Rosenberg, S., B. A. Pulaski, V. K. Clements, L. Qi, M. R. Pipeling, and L. A. Hanyok. 1999. Cell-based vaccines for the stimulation of immunity to metastatic cancers. Immunol. Rev. 170: 101-114.
11. Ostrand-Rosenberg, S., A. Thakur, and V. Clements. 1990. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J. Immunol. 144: 4068-4071.
12. Pulaski, B. A., and S. Ostrand-Rosenberg. 1998. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58: 1486-1493.
13. + T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res. 64: 1867-1874.
14. + T lymphocytes and are potential cancer vaccines. Cancer Res. In press.
15. + T lymphocytes. J. Immunol. 160: 661-666.
16. Qi, L., J. M. Rojas, and S. Ostrand-Rosenberg. 2000. Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo. J. Immunol. 165: 5451-5461.
17. + T lymphocytes provided they do not coexpress invariant chain. Cancer Immunol. Immunother. 53: 525-532.
18. + tumor cells. J. Immunol. 149: 2391-2396.
19. Armstrong, T. D., V. K. Clements, B. K. Martin, J. P. Ting, and S. Ostrand-Rosenberg. 1997. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc. Natl. Acad. Sci. USA 94: 6886-6891.
20. Ochsenbein, A. F., S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. Hemmi, H. Hengartner, and R. M. Zinkernagel. 2001. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411: 1058-1064.
21. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
22. Steinman, R. M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9: 271-296.
23. + T cells by exogenous cell-associated antigens. Immunity 17: 211-220.
24. + T cells. J. Exp. Med. 179: 1539-1549.
25. + tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon-γ. Cancer Immunol. Immunother. 49: 34-45.
26. Ostrand-Rosenberg, S., S. Baskar, N. Patterson, and V. K. Clements. 1996. Expression of MHC class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells. Tissue Antigens 47: 414-421.
27. Johnson, N. A., F. Carland, P. M. Allen, and L. H. Glimcher. 1989. T cell receptor gene segment usage in a panel of hen-egg white lysozyme specific, I-Ak-restricted T helper hybridomas. J. Immunol. 142: 3298-3304.
28. Adorini, L., J. C. Guery, S. Fuchs, V. Ortiz-Navarrete, G. J. Hammerling, and F. Momburg. 1993. Processing of endogenously synthesized hen egg-white lysozyme retained in the endoplasmic reticulum or in secretory form gives rise to a similar but not identical set of epitopes recognized by class II-restricted T cells. J. Immunol. 151: 3576-3586.
29. Wade, W. F., Z. Z. Chen, R. Maki, S. McKercher, E. Palmer, J. C. Gambier, and I. H. Freed. 1989. Altered I-A protein-mediated transmembrane signaling in B cells that express truncated I-Ak protein. Proc. Natl. Acad. Sci. USA 86: 6297-6301.
30. Dolan, B. P., T. P. Phelan, D. Ilkovitch, L. Qi, W. F. Wade, T. M. Laufer, and S. Ostrand-Rosenberg. 2004. Invariant chain and the MHC class II cytoplasmic domains regulate localization of MHC class II molecules to lipid rafts in tumor cell-based vaccines. J. Immunol. 172: 907-914.
31. Ostrand-Rosenberg, S., V. Clements, and L. Marr. 1986. 402AX teratocarcinoma MHC class 1 antigen expression is regulated in vivo by Lyt 1, Lyt 2, and L3T4 expressing splenic T cells. Cell. Immunol. 98: 257-265.
32. Sinha, P., V. K. Clements, and S. Ostrand-Rosenberg. 2005. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174: 636-645.
33. Qi, L., and S. Ostrand-Rosenberg. 2000. MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M. Traffic 1: 152-160.
34. Harshyne, L. A., S. C. Watkins, A. Gambotto, and S. M. Barratt-Boyes. 2001. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J. Immunol. 166: 3717-3723.
35. Herrera, O. B., D. Golshayan, R. Tibbott, F. S. Ochoa, M. J. James, F. M. Marelli-Berg, and R. I. Lechler. 2004. A novel pathway of alloantigen presentation by dendritic cells. J. Immunol. 173: 4828-4837.
36. Vanherberghen, B., K. Andersson, L. M. Carlin, E. N. Nolte-'t Hoen, G. S. Williams, P. Hoglund, and D. M. Davis. 2004. Human and murine inhibitory natural killer cell receptors transfer from natural killer cells to target cells. Proc. Natl. Acad. Sci. USA 101: 16873-16878.
37. Harshyne, L. A., M. I. Zimmer, S. C. Watkins, and S. M. Barratt-Boyes. 2003. A role for class A scavenger receptor in dendritic cell nibbling from live cells. J. Immunol. 170: 2302-2309.
38. + T cells in vivo: the key to rational vaccine design. Annu. Rev. Immunol. 23: 651-682.
39. Wolfers, J., A. Lozier, G. Raposo, A. Regnault, C. Thery, C. Masurier, C. Flament, S. Pouzieux, F. Faure, T. Tursz, et al. 2001. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 7: 297-303.
40. + T cells by dendritic cell-derived exosomes. Nat. Immunol. 3: 1156-1162.
41. Skokos, D., H. G. Botros, C. Demeure, J. Morin, R. Peronet, G. Birkenmeier, S. Boudaly, and S. Mecheri. 2003. Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. J. Immunol. 170: 3037-3045.
42. Bevan, M. J. 1976. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143: 1283-1288.
43. Heath, W. R., and F. R. Carbone. 2001. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19: 47-64.
44. Bedford, P., K. Garner, and S. C. Knight. 1999. MHC class II molecules transferred between allogeneic dendritic cells stimulate primary mixed leukocyte reactions. Int. Immunol. 11: 1739-1744.
45. Russo, V., D. Zhou, C. Sartirana, P. Rovere, A. Villa, S. Rossini, C. Traversari, and C. Bordignon. 2000. Acquisition of intact allogeneic human leukocyte antigen molecules by human dendritic cells. Blood 95: 3473-3477.
46. Vincent-Schneider, H., P. Stumptner-Cuvelette, D. Lankar, S. Pain, G. Raposo, P. Benaroch, and C. Bonnerot. 2002. Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T cells. Int. lmmunol. 14: 713-722.
47. Andre, F., N. Chaput, N. E. Schartz, C. Flament, N. Aubert, J. Bernard, F. Lemonnier, G. Raposo, B. Escudier, D. H. Hsu, et al. 2004. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J. Immunol. 172: 2126-2136.
48. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95: 1178-1183.
49. Sotomayor, E. M., I. Borrello, F. M. Rattis, A. G. Cuenca, J. Abrams, K. Staveley-O'Carroll, and H. I. Levitsky. 2001. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 98: 1070-1077.
50. Pardoll, D. 2003. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21: 807-839.
51. Stumptner-Cuvelette, P., and P. Benaroch. 2002. Multiple roles of the invariant chain in MHC class II function. Biochim. Biophys. Acta 1542: 1-13.
52. Muntasell, A., M. Carrascal, I. Alvarez, L. Serradell, P. van Veelen, F. A. Verreck, F. Koning, J. Abian, and D. Jaraquemada. 2004. Dissection of the HLA-DR4 peptide repertoire in endocrine epithelial cells: strong influence of invariant chain and HLA-DM expression on the nature of ligands. J. Immunol. 173: 1085-1093.